The use of omalizumab for treatment‐refractory chronic spontaneous urticaria in a West Australian outpatient cohort

There is a lack of real‐world data on the use of omalizumab in treatment‐refractory chronic spontaneous urticaria (CSU). A single‐centre retrospective cohort study was performed to assess the efficacy and safety of omalizumab for treatment‐refractory CSU. The overall response rate of 67% is comparab...

Full description

Saved in:
Bibliographic Details
Published inInternal medicine journal Vol. 49; no. 4; pp. 526 - 528
Main Authors Farrah, Georgia, Stevenson, Brittany, Lie, Katie, Brusch, Anna
Format Journal Article
LanguageEnglish
Published Melbourne John Wiley & Sons Australia, Ltd 01.04.2019
Wiley Subscription Services, Inc
Subjects
Adult
Aged
Anti-Allergic Agents - therapeutic use
chronic spontaneous urticaria
Chronic Urticaria - drug therapy
Disease control
Female
Humans
Immunoglobulin E
Immunotherapy
Male
Middle Aged
Monoclonal antibodies
omalizumab
Omalizumab - therapeutic use
Remission
Remission Induction
Retreatment
Retrospective Studies
safety
treatment
Treatment Outcome
treatment‐refractory
Urticaria
Western Australia
Young Adult
Western Australia
treatment
omalizumab
chronic spontaneous urticaria
safety
treatment-refractory
Online AccessGet full text

Cover

More Information
Summary:There is a lack of real‐world data on the use of omalizumab in treatment‐refractory chronic spontaneous urticaria (CSU). A single‐centre retrospective cohort study was performed to assess the efficacy and safety of omalizumab for treatment‐refractory CSU. The overall response rate of 67% is comparable with that reported in the literature. Disease control and sustained remission can be achieved with omalizumab, even in patients with treatment‐resistant CSU.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1444-0903
1445-5994
DOI:10.1111/imj.14245